MBRX Insider Trading Activity and SEC Form 4 Filings
MBRX insider trading summary
Over the past 12 months, insiders at Moleculin Biotech, Inc. (MBRX) reported 3 open-market purchases worth $0 by 3 insiders and no sales on SEC Form 4. Net insider buying was $0.
Latest MBRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 3, 2026 | Jonathan P. Foster | Chief Financial Officer | Buy | $0 (293,333 @ $0.00) |
| Aug 3, 2026 | Walter V Klemp | CEO and President | Buy | $0 (533,333 @ $0.00) |
| Aug 3, 2026 | Donald H Picker | Chief Science Officer | Buy | $0 (173,333 @ $0.00) |
| Jun 23, 2025 | Jonathan P. Foster | Chief Financial Officer | Buy | $100K (270,270 @ $0.37) |
| Jun 23, 2025 | Walter V Klemp | CEO and President | Buy | $250K (675,675 @ $0.37) |
| Dec 26, 2023 | Robert E. George | Director | Buy | $10K (14,493 @ $0.69) |
| Dec 26, 2023 | Jonathan P. Foster | Chief Financial Officer | Buy | $20K (28,986 @ $0.69) |
| Dec 26, 2023 | Walter V Klemp | CEO and President | Buy | $130K (188,404 @ $0.69) |
| Nov 25, 2022 | Walter V Klemp | CEO and President | Buy | $58K (45,000 @ $1.28) |
| Nov 21, 2022 | Walter V Klemp | CEO and President | Buy | $26K (22,500 @ $1.15) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.